A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
B-cell Non-Hodgkin Lymphoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 164 (planned)
- Started
- Sep 24, 2025
- Main results expected
- Jul 4, 2028
- Fully finished
- Feb 15, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of participants with dose-limiting toxicities (DLTs) during the DLT period
Measured over: Up to 4 weeks
Frequency, duration, severity of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs) and Serious Adverse Events (SAEs)
Measured over: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Frequency of SAEs/AEs leading to discontinuation of study treatment
Measured over: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Number of participants with clinically significant alterations in vitals signs and abnormal laboratory parameters
Measured over: From the first dose up to and including 30 (+7) days after the last dose of study treatment , but prior to subsequent cancer therapy
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07123454 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC